Sangivamycin hydrochloride

Sangivamycin hydrochloride is a synthetic nucleoside analog with potential antiviral, anticancer, and antitumor properties. It works by inhibiting protein kinase C (PKC) and interfering with RNA and DNA synthesis, making it toxic to rapidly dividing cells. Originally developed as an anticancer agent, it has also shown broad-spectrum antiviral activity, including against viruses like Ebola, cytomegalovirus (CMV), and SARS-CoV-2 in preclinical studies. Although not widely approved for clinical use, it remains of interest in oncology and infectious disease research. The directory classifies it as a discontinued API with a fermentation-derived source/manufacturing origin. Other names for this substance include Sauzivamycin, 4-amino-7-[3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2 and 3-d]pyrimidine-5-carboxamide;hydrochloride. Its PubChem CID is 5351239.

CAS No 21090-35-7
Molecular Formula C12H16ClN5O5
Molecular Weight 345.74 g/mol
Synonyms 4-amino-7-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide;hydrochloride

Frequently Asked Questions